Evidence review | 1 October 2026
Cannabinoids for spasticity in multiple sclerosis: a systematic review
A review of 27 randomised trials with more than 3,000 participants found that THC:CBD extracts reduced patient-reported spasticity in multiple sclerosis (MS).
A CBMA summary of the study. The full study and its source are available to members.
A team of researchers analysed 27 randomised controlled trials of natural and synthetic cannabinoids for spasticity related to multiple sclerosis.
Extracts combining tetrahydrocannabinol and cannabidiol (THC:CBD) reduced patient-reported spasticity compared with placebo, a result confirmed by a network meta-analysis. Adverse events were mostly mild to moderate, and serious events were rare.
The authors recommend cannabinoids as an adjunctive therapy with appropriate safety monitoring, and call for further high-quality trials.
The full study and its source are for members
The complete evidence database, with the source of every study, is available in the member area.
Member area